THE Therapeutic Goods Administration (TGA) has released its compliance principles for 2026-27, outlining its strategic approach to monitoring and enforcing regulatory compliance for the import, export, manufacture, supply and advertising of therapeutic goods in Australia.
The regulator also announced its 12 priority focus areas for compliance and enforcement activities the first three months of 2026.
Among them are medicinal cannabis, vaping goods, sunscreen, direct-to-consumer in vitro diagnostic kits, erectile dysfunction medicines, melatonin, listed medicine advertising, and weight loss medications.
The new compliance principles are the result of a 2025 review of the TGA's 2023-2025 Compliance Priorities, with a realigned approach focusing on five core themes:
* Safeguarding therapeutic goods to ensure protection from unsafe products
* Proactively engaging with the public, health professionals, industry and other stakeholders
* Protecting and engaging those most vulnerable
* Providing an active response to digital and technology risks
* Strengthening enforcement.
The principles complement the TGA's Regulatory Compliance Framework, which describes how compliance is encouraged and how the regulator responds to alleged contraventions of the law.
"Our 2026 and 2027 compliance principles and focus areas detail the how and why we act: to safeguard Australians from unsafe products, empower the community with clearer information, and take firm, proportionate action when the rules are broken or ignored," explained TGA head Professor Anthony Lawler.
Learn more HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Jan 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Jan 26
